Agreement in Principle for the Acquisition of Fukuroi Factory of API CorporationAcquisition Agreement • November 9th, 2021
Contract Type FiledNovember 9th, 2021SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereinafter the “Company”), hereby announces that SBI ALA Hong Kong Co., Ltd. (hereinafter “SBI ALA Hong Kong”), a subsidiary of the Company and intermediate holding company for the business in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, has agreed in principle to acquire at the target date of August 1st , 2016, Fukuroi Factory (Location: Fukuroi-shi, Shizuoka; hereinafter the “Factory”) of API Corporation (Head office: Chiyoda-ku, Tokyo; Representative Director: Kiyoshi Kondo), a company under the umbrella of the Life Science Institute, Inc., engaged in contracted manufacture of active pharmaceutical ingredients, pharmaceutical intermediates and investigational new drugs. The Factory has been manufacturing so far some of investigational drugs containing 5-ALA, and the SBI group will expand the production of 5-ALA rela